What is the current liquidity situation, bank line, and interest rate?

The CFO stated the net leverage ratio is 1.85x with an effective interest rate of 5.6%. The goal is to reduce leverage to 1.5x-1.75x by the end of the fiscal year. “Yes, we're currently at 1.85x, Paul, with an effective interest rate of 5.6%. And our goal over the remainder of the fiscal year is to drive that down somewhere between 1.75x and 1.5x.”

Have conditions eased in the China market?

The CEO stated that the China market still has structural issues and headwinds, but Mesa's revenue exposure to China is now substantially lower than $3.5 million and has declined significantly over the last two years. “Look, I think China market has structural issues. As you know, our revenue from China at this point is substantially lower than $3.5 million. It's a pretty small part of our company's overall revenue.”

More color on execution fixes, associated costs, and where they are in the process. Also, market growth context for future guidance.

The CEO highlighted talent changes (new BPD GM, SVP of Operations focused on SDC), significant resource and mindshare commitment to fix issues, and a cultural shift towards a growth mindset and efficient capital reallocation. He declined to provide market growth commentary or guidance details before the November call. “We have a new general manager starting. We've also reallocated the full focus of our SVP of Operations on fixing the operations issues. So part of it is actually just talent and significant resource commitment and actually, frankly, mindshare commitment has been towards areas that we know we can fix completely under our own control.”

MLAB

Mesa Laboratories (MLAB) Q1 FY27 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q1 FY27)· Health Care· Aug 10, 2026

Source: earnings call transcript

Executive summary

Mesa Laboratories Q1 FY27 — Strong Operational Turnaround and Deleveraging Progress

Mesa Laboratories delivered a strong operational turnaround in Q1 FY27, with positive organic revenue growth and significant adjusted operating income expansion, driven by improved performance in BPD and other segments. The new CEO emphasized a focus on execution and capital reallocation to high-return businesses, while actively managing the portfolio and committing to full-year guidance in November. Despite SDC's delivery challenges, the underlying demand remains healthy, and the company made substantial progress on deleveraging.

Highlights

Total revenues increased 1% year-over-year to $60.1 million, driven by organic growth.
Adjusted operating income (excluding legal settlement) grew 19.5% to $15.4 million, with margin expanding 390 basis points to 25.6% of revenues.
Biopharmaceutical Development (BPD) segment grew 5% organically, a significant turnaround from a 30% decline in the prior quarter.
Net leverage ratio reduced to 1.85x, with $8.7 million of debt repaid this quarter, moving towards a target of 1.5x to 1.75x by FY27 end.
Operating cash flows significantly improved, providing $14.7 million, a $12.8 million year-over-year increase.

Concerns

Sterilization and Disinfection Controls (SDC) reported organic revenue declined 3.6% year-over-year due to delivery reliability issues, with past due backlog increasing by $1 million from year-end.
GAAP net income decreased 40.3% to $2.8 million, primarily due to non-cash foreign currency rate changes on an intercompany loan.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year FY27 Guidance	Will be provided high materiality	FY27	High
Biopharmaceutical Development (BPD) Full-Year Growth	Grow for the full year medium materiality	FY27	High
Net Leverage Ratio	1.5x to 1.75x high materiality	End of FY27	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Sterilization and Disinfection Controls (SDC) Revenue decline due to delivery reliability issues, not demand. Underlying demand is healthy. Gross profit percentage decreased due to lower revenues on a partially fixed cost base and product mix. Management is focused on reducing process variability without compromising quality standards to improve delivery. Trailing 12-month revenue: $101 millionTrailing 12-month growth: ~5%Past due backlog increase: $1 million (from year-end low)	$24.5 million	-3.6% organic decline	—	Gross profit percentage decreased 150 basis points
Biopharmaceutical Development (BPD) Strong organic growth driven by higher immunoassay hardware and consumables volumes and price. Gross profit percentage improved due to a higher mix of immunoassay consumables, supply chain efficiencies, and operating leverage. Management is rebuilding the commercial engine and accelerating the next-generation Gyrolab platform development. Immunoassay hardware and consumables volumes: higherNext-generation Gyrolab platform launch: expected FY28	$12.1 million	5% organically	—	Gross profit percentage increased 800 basis points
Calibration Solutions Consistent organic growth, contributing steadily to the overall business. Gross profit percentage improved due to higher revenues on a partially fixed cost base.	$13.3 million	7.6% organically	—	Gross profit percentage increased 350 basis points
Clinical Genomics Essentially flat revenue, with China declining at a slower rate than last year. Business outside China showed slight growth. Gross profit percentage improved due to price and manufacturing/supply chain efficiency improvements. The business is being managed deliberately with attention to cost structure and returns. China revenue decline: 7%Non-China revenue growth: 0.6%	$10.3 million	-0.1% (essentially flat)	—	Gross profit percentage increased 790 basis points

Product announcements

Product	Type	Timeline	Details
Next-generation Gyrolab platform	roadmap	fiscal 2028

Risks & headwinds

SDC Delivery Reliability Issues Current quarter (Q1 FY27) and ongoing.

Reported organic revenue down 3.6% YoY; past due backlog up $1 million from year-end low.

Mitigation:Reducing variability in the process, tightening cycle times without compromising quality standards; SVP of Operations focused on this singular goal.

Quarterly Volatility from Foreign Currency Rates Ongoing, quarter-to-quarter.

Non-operating expense of $2.7 million in Q1 FY27 compared to non-operating income of $3.9 million in prior year, causing a 40.3% decrease in GAAP net income.

Mitigation:Acknowledged as a non-cash item primarily due to unrealized currency gains and losses on an intercompany loan, implying it's a reporting volatility rather than an operational cash flow issue.

China Market Headwinds Ongoing structural issues.

Clinical Genomics China revenue declined 7%.

Mitigation:Mesa's revenue exposure to China has declined significantly over the last two years and is now substantially lower than $3.5 million, reducing overall impact. Managing the Clinical Genomics business deliberately with full attention to cost structure and returns.

Customer Attrition due to Extended Delays Ongoing as long as delivery issues persist.

Not quantified, but acknowledged that 'extended delays invite customers to evaluate alternatives' and 'I'm not going to promise that has cost us nothing anywhere'.

Mitigation:Focus on fixing SDC delivery reliability to convert 'surge work into standard work' and ensure customers can count on Mesa.

What to watch in Q2 FY27

Full-year FY27 Guidance Release

November (next earnings call)

Current Directional commentary provided

Target Full-year FY27 guidance

Why it matters

The new CEO committed to providing comprehensive full-year guidance, which will outline the company's financial outlook and strategic priorities after his first half-year of data and operational changes.

As I committed last quarter, we'll provide full year fiscal 2027 guidance at our next earnings call in November, alongside first half results.

Find out whether MLAB delivers this. Inve re-checks your case every morning.

Q&A highlights

What parts of the business are easiest to build upon, given the historical M&A focus?

The CEO reiterated that the focus is on execution within the existing portfolio, particularly SDC, BPD, and to an extent Clinical Genomics and Calibration Solutions, rather than M&A. He noted that three of the four businesses are growing nicely with good margin profiles.

“The near-term value in this company is self-help, executing the businesses we already own, and deliberately reallocating capital, effort, and management mindshare towards the part of the portfolio that offers the most profitable growth.”

asked by Paul Knight · answered by Siddhartha Kadia

2 min read 5 chapters

Detailed narrative

CEO's First 100 Days and Strategic Focus

CEO Siddhartha Kadia, in his first earnings call, shared insights from his initial 100 days, emphasizing a direct approach to communication and a focus on execution. He visited every major site, met with over half of employees, and engaged with key customers, concluding that Mesa possesses "durable, regulation-embedded franchises with real and growing earnings power that had fixable execution problems." His immediate focus is on self-help, executing existing businesses, and reallocating capital and management attention to the most profitable growth areas, rather than acquisitions.

Biopharmaceutical Development (BPD) Turnaround

The BPD segment demonstrated a significant turnaround, growing 5% organically this quarter after a nearly 30% decline in the previous quarter. While acknowledging easier comparisons and some deferred order catch-up, management is actively rebuilding the commercial engine with a new general manager and expects the full commercial transformation to take about a year.

The company also reprioritized R&D to accelerate the next-generation Gyrolab platform, now expected to launch in fiscal 2028, signaling a renewed innovation focus.

Sterilization and Disinfection Controls (SDC) Delivery Challenges

SDC reported a 3.6% organic revenue decline, attributed to delivery reliability issues rather than a lack of demand. The CEO clarified that past due backlog increased by $1 million from its year-end low, indicating that improvements in throughput were episodic.

The core issue stems from maintaining strict quality standards for biological materials, leading to variability in lot clearance times. Management is focused on reducing process variability without compromising quality, aiming for a durable fix to improve customer delivery.

Balance Sheet Strengthening and Capital Allocation

Mesa continued to strengthen its balance sheet, repaying $8.7 million of debt and reducing its net leverage ratio to 1.85x. The company aims to further reduce this to 1.5x to 1.75x by the end of FY27. This deleveraging reflects a deliberate priority, with the near-term capital allocation strategy focused on internal execution and optimizing existing businesses, rather than M&A, though small tuck-in acquisitions might be considered later in the year.

Margin Expansion and Reinvestment Strategy

The company achieved significant margin expansion, with adjusted operating income (excluding legal settlement) growing 19.5% and margin reaching 25.6% of revenues, a 390 basis point increase. While Q1 is seasonally the lightest volume quarter, management sees an opportunity to reinvest a portion of this operating leverage into faster-growing, higher-return businesses to accelerate growth, rather than solely maximizing current year margins.

This strategic reinvestment will be detailed with full-year guidance in November.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.